GU Specialists

Howard Sandler, MD

Chair of Radiation Oncology at Cedars-Sinai Medical Center  
Ronald H. Bloom Family Chair in Cancer Therapeutics

Dr. Sandler is the Chair of Radiation Oncology at Cedars-Sinai Medical Center. He also holds the Ronald H. Bloom Family Chair in Cancer Therapeutics. Prior to joining Cedars-Sinai, Dr. Sanders served as a professor of radiation oncology and urology at the University of Michigan, and Senior Associate Chair and Departmental Service Chief at the University of Michigan Hospital. Dr. Sandler's research interests include prostate and genito-uriniary tumors as well as a broad range of subjects related to radiation oncology. 


Mack Roach III, MD

Professor of Radiation Oncology and Urology, University of California San Francisco
Chair of Radiation Oncology  

Dr. Roach is recognized as a major authority on the treatment of clinically localized prostate cancer. He served as lead author for the 1996, 2000, and pending 2006 editions of the American College of Radiology Appropriateness Criteria Guidelines for defining how men in this country should be simulated and treated with radiotherapy. He also served on the NCI Intensity Modulated Radiotherapy Working Group to define jargon and criteria for defining the use of new technology. He helped co-author the 2001 prostate cancer screening guidelines put forth by the American Cancer Society. He is best known for the recently completed prospective randomized RTOG trial that demonstrated the value of pelvic nodal radiotherapy for patients with high risk prostate cancer. 

Ronald C. Chen, M.D., M.P.H.
Associate Professor
Cancer Prevention and Control
Director, UNC CyberKnife Radiosurgery Program
Associate Director of Education
Lineberger Comprehensive Cancer Center
University of North Carolina

"Dr. Chen is a GU radiation oncologist with particular clinical interests in prostate and bladder cancers. He is a health services researcher, with research focus on the quality of life in cancer survivors, comparative effectiveness of different treatment approaches for prostate cancer, and patterns of care. Dr. Chen is the director of the UNC Cyberknife program and has clinical expertise in using stereotactic body radiation therapy for the primary treatment of tumors and also for treatment of metastatic sites."

Anthony V. D'Amico, MD, PhD

Eleanor Theresa Walters Distinguished Professor 
Department of Radiation Oncology
Harvard Medical School

Chief, Genitourinary Radiation Oncology
Dana-Farber Cancer Institute
Brigham and Women's Hospital

     Dr. D’Amico is an internationally known expert in the treatment of prostate cancer and has defined combined modality staging, which is used to select patients with localized prostate cancer for specific surgical or radiotheraputic treatment options.  He is the principal investigator of several federally funded grants that support his investigations in Image Guided Therapy for early stage prostate cancer, drug development for advanced stage prostate cancer, and clinical trials that are aimed at defining future management strategies for men with prostate cancer.
     Dr. Anthony D’Amico is currently developing and testing optical and molecular imaging technology, which holds great promise for significantly improving the way in which prostate cancer is detected and treated.  In conjunction with this work, Dr. D’Amico is currently leading the effort towards the creation of a Prostate Cancer Institute in the Harvard Medical Complex. 
     He has over 250 peer reviewed original publications and editorials, and his teaching contributions include his position as Co-director of the Harvard Combined Residency in Radiation Oncology, Master of the Oliver Wendell Holmes Society, editorial board member of 6 scientific journals, expert reviewer for 14 Journals including the New England Journal of Medicine and the Journal of the American Medical Association and editor of four textbooks on the management of prostate cancer.